What Will Drive Biopharma’s Future? The long-dreaded crisis is staring us all in the face: What will take the place of expiring blockbusters with few prospects in hand? Spending on R&D more than doubled after 2002, but the output doesn’t match the investment. The number of new molecular entities has remained a disappointment, averaging only around 20 per year in the US. The big question is how can drug developers carve out a strategic path to innovation?